Synapse - Works

Results (5608)

Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel

Meeting Abstract

Tripathi, A.; Xie, W.; Sweeney, C.; Choudhury, A. D.; Pomerantz, M.; Wei, X. X.; Taplin, M. E.; Choueiri, T. K.; Lee, G. S. M.; Kantoff, P. W.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)

Meeting Abstract

Tannir, N. M.; Naing, A.; Infante, J. R.; Papadopoulos, K. P.; Wong, D. J. L.; Korn, M.; Aljumaily, R.; Autio, K. A.; Pant, S.; Bauer, T. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma

Meeting Abstract

Tannir, N. M.; Motzer, R. J.; Agarwal, N.; Liu, P. Y.; Whiting, S. H.; O'Keeffe, B.; Tran, X.; Fiji, G. P.; Escudier, B.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist)

Meeting Abstract

Slovin, S. F.; Melloni, C.; Mansor-Lefebvre, S.; Neijber, A.; Roe, M.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial

Meeting Abstract

Small, E. J.; Saad, F.; Rathkopf, D. E.; Hadaschik, B. A.; Chowdhury, S.; Yu, M. K.; Lopez-Gitlitz, A.; Rooney, O. B.; Shu, Y.; Darif, M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial

Meeting Abstract

Smith, M. R.; Saad, F.; Rathkopf, D. E.; Hadaschik, B. A.; Chowdhury, S.; Yu, M. K.; Lopez-Gitlitz, A.; Rooney, O. B.; Darif, M.; Small, E. J.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas

Meeting Abstract

Shen, R.; Martin, A.; Ni, A.; Hellmann, M. D.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; Arbour, K. C.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples

Meeting Abstract

Scher, H. I.; Dago, A. E.; Lee, J.; Sutton, R.; Graf, R. P.; Schreiber, N. A.; Hullings, M.; Wang, Y.; Landers, M. A.; Solit, D. B.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Schonhoft, J.; Graf, R. P.; Dago, A. E.; Lee, J.; Sutton, R.; Schreiber, N. A.; Hullings, M.; Jendrisak, A.; Wang, Y.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

Meeting Abstract

Sanborn, R. E.; Menke, C. W.; Autio, K. A.; Arkenau, H. T.; Corbacho, J. G.; LoRusso, P.; Plummer, E. R.; Uboha, N. V.; Freeman, M. L.; Wydmanski, J.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save